Spyre Therapeutics (SYRE) Beats Q4 Earnings Estimates by $0.04

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly earnings results on February 19, 2026 that exceeded analyst expectations.

The Healthcare company reported earnings per share of $-0.70, beating the consensus estimate of $-0.74 by $0.04 per share. Revenue came in at , missing the estimate of $111.1K.

Spyre Therapeutics's stock moved following the earnings release. The stock currently trades at $39.96 with a market capitalization of $2.1B.